Current Issue

BioPharm International: Feb 06, 2015
Changes in the country’s political landscape may affect the pharmaceutical industry market in the future.
BioPharm International: Feb 01, 2015
The author discusses the various ways in which a quality-by-design program can enhance the extractable and leachable assessment of a drug product.
BioPharm International: Feb 01, 2015
The use of commercially available media to achieve high titer in early process development is discussed.
BioPharm International: Feb 01, 2015
EMA is under pressure to exert even tighter standards on biosimilars being marketed in Europe.
BioPharm International: Feb 01, 2015
Understanding the influence of change events on product performance is a necessity to routine drug development, transfer, and validation.
BioPharm International: Feb 01, 2015
Investors are lining up for the biosimilars market as patents reach expiration and regulatory pathways are defined.
BioPharm International: Feb 01, 2015
Market forces may limit the success of CMOs.
BioPharm International: Feb 01, 2015
Manufacturers face new rules for tracing drugs through the supply chain and compounders face stricter standards.
BioPharm International: Feb 01, 2015
Evaluating the assembly design process, manufacture, and use helps mitigate risk.
BioPharm International: Feb 01, 2015
Initiatives to speed drug development must pass Congress and special interest groups.